Dublin, Jan. 05, 2022 (GLOBE NEWSWIRE) -- The "Narcolepsy Drugs Market by Disease and Therapeutic Type: Global Opportunity Analysis and Industry Forecast, 2021-2030" report has been added to ResearchAndMarkets.com's offering.
The narcolepsy drugs market was valued at $2,680.06 million in 2020, and is projected to reach $6,667.80 million by 2030, registering a CAGR of 9.6% from 2021 to 2030.
Narcolepsy is mainly a long-term neurological disorder characterized by a classic tetrad of excessive daytime sleepiness with irresistible sleep attacks, cataplexy (sudden bilateral loss of muscle tone), hypnagogic hallucination, and sleep paralysis. Around 70% individuals experience episodes of sudden loss of muscle strength, this is often referred to as cataplexy, which can be brought on by strong emotions. Less commonly, there may be inability to move or vivid hallucinations when falling asleep or waking up. People with narcolepsy tend to sleep about the same number of hours per day as people without, but the quality of sleep tends to be worse.
Narcolepsy is a rare and under-diagnosed chronic condition affecting both males and females equally. The severity of the disease and rise in number of individuals being affected by narcolepsy are the factors that drive the market growth. Furthermore, the availability of reimbursement process for FDA-approved prescription medicines help increase the demand for these drugs. However, lack of awareness regarding the diagnosis and treatment availability is predicted to hinder the market growth. There is an increase in the number of programs organized by various organizations mainly due to surge in awareness, which is anticipated to provide lucrative opportunities for the market growth.
The narcolepsy drugs market is segmented on the basis of disease type, therapeutics type, and region. By disease type, the market is classified into daytime extreme sleepiness, cataplexia, and other disease type. By therapeutics type, the market is divided into central nervous system stimulants, tricyclic antidepressants, sodium oxybate, selective serotonin reuptake inhibitor, and other therapeutic type. By region, the global narcolepsy drugs market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
This report provides comprehensive competitive analysis and profiles of prominent market players such Arena Pharmaceuticals, Inc., Bioprojet Company, Graymark Healthcare, Inc., Hikma Pharmaceuticals PLC, Jazz Pharmaceuticals plc, Ligand Pharmaceuticals Incorporated, Shionogi Inc., Takeda Pharmaceutical Company Limited, Novartis International AG, and Teva Pharmaceutical Industries Limited.
Key Benefits
- The study provides an in-depth analysis of the global Narcolepsy drugs market along with the current trends and future estimations to elucidate the imminent investment pockets.
- A comprehensive analysis of the factors that drive and restrict the market growth is provided in the report.
- Comprehensive quantitative analysis of the industry from 2020 to 2030 is provided to enable the stakeholders to capitalize on the prevailing market opportunities.
- Extensive analysis of the key segments of the industry helps to understand the products and end users of Narcolepsy drugs used across the globe.
- Key market players and their strategies have been analysed to understand the competitive outlook of the market.
Key Topics Covered:
CHAPTER 1: INTRODUCTION
CHAPTER 2: EXECUTIVE SUMMARY
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.2.2. Top winning strategies
3.3. Porter's five forces analysis
3.4. Top player positioning
3.5. Market dynamics
3.5.1. Drivers, restraints, and opportunity
3.5.2. Drivers
3.5.2.1. Increase in global prevalence of narcolepsy
3.5.2.2. Narcolepsy awareness programs and services
3.5.2.3. Presence of reimbursement policies regarding narcolepsy
3.5.3. Restraints
3.5.3.1. Adverse effects and risks related to narcolepsy drugs
3.5.3.2. Delayed diagnosis or misdiagnosis
3.5.4. Opportunity
3.5.4.1. Untapped markets in the developing countries
3.6. Impact of COVID-19 on the NARCOLEPSY DRUG market
3.6.1. Overview
3.6.2. Impact analysis
CHAPTER 4: NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. Daytime extreme sleepiness
4.2.1. Key market trends and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market analysis, by country
4.3. Cataplexia
4.3.1. Key market trends and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market analysis, by country
4.4. Other disease type
4.4.1. Key market trends and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market analysis, by country
CHAPTER 5: NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE
5.1. Overview
5.1.1. Market size and forecast
5.2. Central nervous system stimulants
5.2.1. Market size and forecast, by region
5.2.2. Market analysis, by country
5.3. Tricyclic antidepressants
5.3.1. Market size and forecast, by region
5.3.2. Market analysis, by country
5.4. Sodium oxybate
5.4.1. Market size and forecast, by region
5.4.2. Market analysis, by country
5.5. Selective serotonin reuptake inhibitor
5.5.1. Market size and forecast, by region
5.5.2. Market analysis, by country
5.6. Other therapeutic type
5.6.1. Market size and forecast, by region
5.6.2. Market analysis, by country
CHAPTER 6: NARCOLEPSY DRUGS MARKET, BY REGION
CHAPTER 7: COMPANY PROFILES153
7.1. Arena Pharmaceuticals, Inc.
7.1.1. Company overview
7.1.2. Operating business segments
7.1.3. Product portfolio
7.1.4. Business performance
7.2. BIOPROJET COMPANY
7.2.1. Company overview
7.2.2. Operating business segments
7.2.3. Product portfolio
7.3. GRAYMARK HEALTHCARE, INC.
7.3.1. Company overview
7.3.2. Company snapshot
7.3.3. Operating business segments
7.3.4. Product portfolio
7.4. Hikma Pharmaceuticals Plc
7.4.1. Company overview
7.4.2. Operating business segments
7.4.3. Product portfolio
7.4.4. Business performance
7.4.5. Key strategic moves and developments
7.5. JAZZ PHARMACEUTICALS PLC
7.5.1. Company overview
7.5.2. Operating business segments
7.5.3. Product portfolio
7.5.4. Business performance
7.5.5. Key strategic moves and developments
7.6. LIGAND PHARMACEUTICALS, INC.
7.6.1. Company overview
7.6.2. Company snapshot
7.6.3. Operating business segments
7.6.4. Product portfolio
7.6.5. Business performance
7.6.6. Key strategic moves and developments
7.7. Shionogi Inc.
7.7.1. Company overview
7.7.2. Operating business segments
7.7.3. Product portfolio
7.7.4. Business performance
7.8. Takeda Pharmaceutical Company Limited
7.8.1. Company overview
7.8.2. Company snapshot
7.8.3. Operating business segments
7.8.4. Product portfolio
7.8.5. Business performance
7.9. NOVARTIS INTERNATIONAL AG
7.9.1. Company overview
7.9.2. Company snapshot
7.9.3. Operating business segments
7.9.4. Product portfolio
7.9.5. Business performance
7.10. TEVA PHARMACEUTICAL INDUSTRIES LIMITED
7.10.1. Company overview
7.10.2. Company snapshot
7.10.3. Operating business segments
7.10.4. Product portfolio
7.10.5. Business performance
For more information about this report visit https://www.researchandmarkets.com/r/f5g8jk
